ClinicalTrials.gg
CompletedNCT00076024Updated Jun 26, 2012Results posted

AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer

A Phase 1/2 interventional study of Placebo and Docetaxel in Breast Neoplasms, sponsored by Pfizer. Completed at 54 sites in 8 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-26.

Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
174
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 182 studies in Breast Neoplasms by Pfizer — 6 open to participants now, 26 under way, 7 of them phase 3. Breast Neoplasms · Pfizer.

Enrollment
39th of 121
174 · median 75
Started
2004
with 4 others
Phase 1/2
13 of 182
none open now
Registered
13th of 182
by date

Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 39th largest by enrollment of the 121 interventional ones that give a count, is one of 5 that started in 2004, is one of 13 in phase 1/2, and was the 13th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 182 studies in Breast Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 182 studies in Breast Neoplasms by Pfizer, or all of them as a file.
02

Study summary

The primary purpose of the study is to determine the time to progression of the combination of study drug (AG-013736) and docetaxel versus docetaxel alone in patients who have not received prior chemotherapy for metastatic breast cancer. The secondary purpose of the study is to determine the dose of study drug that can be given with docetaxel administered on an every 3 week schedule.

03

Conditions studied

  • Breast Neoplasms

Browse trials for

Keywords

  • metastatic breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients with histologically/ proven breast carcinoma (stage IV, or recurrent with local or regional spread or distant metastatic disease)
  • Adequate bone marrow, liver, and renal function

Exclusion criteria

Exclusion Criteria:

  • chemotherapy given in the past 12 months
  • Uncontrolled
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
174 participants (actual)

Study arms

  • Other
    Docetaxel + Placebo

    Docetaxel + Placebo

    Drug: Placebo · Drug: Docetaxel

  • Experimental
    Docetaxel + AG-013736

    Docetaxel + AG-013736

    Drug: AG-013736 (axitinib) · Drug: Docetaxel

Interventions

  • DrugPlacebo

    5 mg twice daily \[bid\] continuous dosing

  • Standard of care drug administration

  • 5mg twice daily \[bid\] continuous dosing

  • Standard of care drug administration

06

What researchers measure

Primary outcomes

  1. Time to Tumor Progression (TTP)

    Time in days from start of study treatment to first documentation of objective tumor progression or death due to cancer, whichever comes first. TTP was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]).

    Time frame: Phase 2 double-blind baseline until tumor progression or death or discontinuation from study treatment, assessed every 9 weeks up to 129 weeks

Secondary outcomes

  1. Percentage of Participants With Objective Response (OR) for Phase 2 (Double-blind)

    Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

    Time frame: Phase 2 double- blind baseline until the date of first documented progression or discontinuation from the study treatment due to any cause, assessed every 9 weeks up to 129 weeks

  2. Percentage of Participants With Objective Response (OR) for Phase 2 (Open-label)

    Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

    Time frame: Phase 2 open-label baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 58 weeks

  3. Duration of Response (DR) for Phase 2 (Double-blind)

    Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

    Time frame: Phase 2 double-blind baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 9 weeks up to 129 weeks

  4. Duration of Response (DR) for Phase 2 (Open-label)

    Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

    Time frame: Phase 2 open-label baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 58 weeks

Other outcomes

  1. Population Pharmacokinetics of Axitinib (AG-013736) for Phase 2 (Double-blind)

    Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

    Time frame: Day 1 (pre-dose), Day 22 and Day 43 and then every 9 weeks up to 129 weeks

07

Results

Posted Mar 16, 2012
Limitations and caveats
Analysis of TTP (Phase 2, Double-blind) was performed with both discontinuation due to lack of efficacy (LOE) considered a progression and not considered a progression event. Latter was considered primary analysis and former a sensitivity analysis.

Participant flow

Phase 1, Lead-in
Participant flow — Phase 1, Lead-in
MilestoneAxitinib + Docetaxel (Phase-1, Lead-in)Axitinib + Docetaxel (Phase 2, Double-blind)Docetaxel + Placebo (Phase 2, Double-blind)Axitinib (Phase 2, Open-label)
Started6000
Completed0000
Not completed6000
Withdrew: Lack of efficacy4000
Withdrew: Adverse event1000
Withdrew: Clinical progression1000
Phase 2, Double-blind
Participant flow — Phase 2, Double-blind
MilestoneAxitinib + Docetaxel (Phase-1, Lead-in)Axitinib + Docetaxel (Phase 2, Double-blind)Docetaxel + Placebo (Phase 2, Double-blind)Axitinib (Phase 2, Open-label)
Started0112560
Treated0111560
Completed0000
Not completed0112560
Withdrew: Lack of efficacy059400
Withdrew: Withdrawal by subject01340
Withdrew: Adverse event02560
Withdrew: Un-specified01460
Withdrew: Randomized but not treated0100
Phase 2, Open-label
Participant flow — Phase 2, Open-label
MilestoneAxitinib + Docetaxel (Phase-1, Lead-in)Axitinib + Docetaxel (Phase 2, Double-blind)Docetaxel + Placebo (Phase 2, Double-blind)Axitinib (Phase 2, Open-label)
Started00016
Completed0000
Not completed00016
Withdrew: Adverse event0002
Withdrew: Lack of efficacy00011
Withdrew: Withdrawal by subject0001
Withdrew: Other0002

Outcome measures

PrimaryTime to Tumor Progression (TTP)

Time in days from start of study treatment to first documentation of objective tumor progression or death due to cancer, whichever comes first. TTP was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]).

Time frame:
Phase 2 double-blind baseline until tumor progression or death or discontinuation from study treatment, assessed every 9 weeks up to 129 weeks
Reported as:
Median · days
Time to Tumor Progression (TTP)
daysAxitinib + Docetaxel (Phase 2, Double-blind)Docetaxel + Placebo (Phase 2, Double-blind)
Time to Tumor Progression (TTP)247 (208 to 265)215 (191 to 247)
Statistical analysis
  • Axitinib + Docetaxel (Phase 2, Double-blind) vs Docetaxel + Placebo (Phase 2, Double-blind) · Log Rank · p = 0.156 · Hazard ratio (hr): 1.237 · 95% CI 0.819 to 1.867One-sided log-rank test at alpha = 0.1 significance level was used.
SecondaryPercentage of Participants With Objective Response (OR) for Phase 2 (Double-blind)

Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

Time frame:
Phase 2 double- blind baseline until the date of first documented progression or discontinuation from the study treatment due to any cause, assessed every 9 weeks up to 129 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (OR) for Phase 2 (Double-blind)
percentage of participantsAxitinib + Docetaxel (Phase 2, Double-blind)Docetaxel + Placebo (Phase 2, Double-blind)
Percentage of Participants With Objective Response (OR) for Phase 2 (Double-blind)41.1 (31.9 to 50.8)23.6 (13.2 to 37.0)
Statistical analysis
  • Axitinib + Docetaxel (Phase 2, Double-blind) vs Docetaxel + Placebo (Phase 2, Double-blind) · Fisher Exact · p = 0.038 · Difference in response rates: 17.4 · 95% CI 3.0 to 31.9
SecondaryPercentage of Participants With Objective Response (OR) for Phase 2 (Open-label)

Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

Time frame:
Phase 2 open-label baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 58 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (OR) for Phase 2 (Open-label)
percentage of participantsAxitinib (Phase 2, Open-label)
Percentage of Participants With Objective Response (OR) for Phase 2 (Open-label)6.3 (0.2 to 30.2)
SecondaryDuration of Response (DR) for Phase 2 (Double-blind)

Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

Time frame:
Phase 2 double-blind baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 9 weeks up to 129 weeks
Reported as:
Median · days
Duration of Response (DR) for Phase 2 (Double-blind)
daysAxitinib + Docetaxel (Phase 2, Double-blind)Docetaxel + Placebo (Phase 2, Double-blind)
Duration of Response (DR) for Phase 2 (Double-blind)211 (190 to 276)149 (120 to 238)
SecondaryDuration of Response (DR) for Phase 2 (Open-label)

Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

Time frame:
Phase 2 open-label baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 58 weeks
Reported as:
Median · days
Duration of Response (DR) for Phase 2 (Open-label)
daysAxitinib (Phase 2, Open-label)
Duration of Response (DR) for Phase 2 (Open-label)1.0 (NA to NA)
Other pre-specifiedPopulation Pharmacokinetics of Axitinib (AG-013736) for Phase 2 (Double-blind)

Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

Time frame:
Day 1 (pre-dose), Day 22 and Day 43 and then every 9 weeks up to 129 weeks
Reported as:
Mean · nanogram/milliliter (ng/mL)

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axitinib + Docetaxel (Phase-1 Lead-in)—1/6 (16.7%)6/6 (100%)
Axitinib + Docetaxel (Phase 2, Double-blind)—54/111 (48.6%)111/111 (100%)
Docetaxel + Placebo (Phase 2, Double-blind)—17/56 (30.4%)56/56 (100%)
Axitinib (Phase 2, Open-label)—2/16 (12.5%)12/16 (75%)
Most frequent serious events
Showing 10 of 79
Most frequent serious events
EventAxitinib + Docetaxel (Phase-1 Lead-in)Axitinib + Docetaxel (Phase 2, Double-blind)Docetaxel + Placebo (Phase 2, Double-blind)Axitinib (Phase 2, Open-label)
Febrile neutropeniaBlood and lymphatic system disorders1/69/1113/560/16
StomatitisGastrointestinal disorders1/65/1110/560/16
NeutropeniaBlood and lymphatic system disorders0/610/1113/560/16
HypothyroidismEndocrine disorders0/60/1110/561/16
ConvulsionNervous system disorders0/60/1110/561/16
PyrexiaGeneral disorders0/66/1111/560/16
DiarrhoeaGastrointestinal disorders0/64/1111/560/16
NauseaGastrointestinal disorders0/64/1112/560/16
VomitingGastrointestinal disorders0/64/1112/560/16
DehydrationMetabolism and nutrition disorders0/64/1111/560/16
Most frequent other events
Showing 10 of 167
Most frequent other events
EventAxitinib + Docetaxel (Phase-1 Lead-in)Axitinib + Docetaxel (Phase 2, Double-blind)Docetaxel + Placebo (Phase 2, Double-blind)Axitinib (Phase 2, Open-label)
DiarrhoeaGastrointestinal disorders5/669/11124/564/16
NauseaGastrointestinal disorders5/654/11119/5610/16
Nail disorderSkin and subcutaneous tissue disorders5/623/11114/560/16
NeutropeniaBlood and lymphatic system disorders4/639/11120/560/16
Abdominal painGastrointestinal disorders4/626/1115/562/16
Oral painGastrointestinal disorders4/611/1115/563/16
VomitingGastrointestinal disorders4/642/11117/565/16
FatigueGeneral disorders4/652/11124/567/16
DehydrationMetabolism and nutrition disorders4/612/1110/561/16
DysgeusiaNervous system disorders4/625/11110/561/16

Baseline characteristics

Age Continuous
Age Continuous(Years)Axitinib + Docetaxel (Phase 1, Lead-in)Axitinib + Docetaxel (Phase 2, Double-blind)Docetaxel + Placebo (Double-blind)Total
Mean50.80 ± 9.6854.10 ± 10.4354.70 ± 10.1254.2 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Axitinib + Docetaxel (Phase 1, Lead-in)Axitinib + Docetaxel (Phase 2, Double-blind)Docetaxel + Placebo (Double-blind)Total
Female611256174
Male0000
08

Study locations

54 sites
  • Pfizer Investigational Site
    Tucson, Arizona 85724-5024, United States
  • Pfizer Investigational Site
    Tucson, Arizona 85724, United States
  • Pfizer Investigational Site
    Berkeley, California 94704, United States
  • Pfizer Investigational Site
    Montebello, California 90640, United States
  • Pfizer Investigational Site
    Monterey Park, California 91754, United States
  • Pfizer Investigational Site
    San Francisco, California 94115, United States
  • Pfizer Investigational Site
    San Gabriel, California 91776, United States
  • Pfizer Investigational Site
    Whittier, California 90602, United States
  • Pfizer Investigational Site
    Jacksonville Beach, Florida 32250, United States
  • Pfizer Investigational Site
    Jacksonville, Florida 32204, United States
  • Pfizer Investigational Site
    Jacksonville, Florida 32207, United States
  • Pfizer Investigational Site
    Jacksonville, Florida 32223, United States
  • Pfizer Investigational Site
    Melbourne, Florida 32901, United States
  • Pfizer Investigational Site
    Orange Park, Florida 32073, United States
  • Pfizer Investigational Site
    Palatka, Florida 32177, United States
  • Pfizer Investigational Site
    St. Augustine, Florida 32086, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60612, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60637, United States
  • Pfizer Investigational Site
    Zion, Illinois 60099, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02118, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan 48106, United States
  • Pfizer Investigational Site
    Stony Brook, New York 11794, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44195, United States
  • Pfizer Investigational Site
    Corvallis, Oregon 97330, United States
  • Pfizer Investigational Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Pfizer Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H2L 4M1, Canada
  • Pfizer Investigational Site
    Novy Jicin, 741 01, Czech Republic
  • Pfizer Investigational Site
    Praha 8, 180 00, Czech Republic
  • Pfizer Investigational Site
    Berlin, 10117, Germany
  • Pfizer Investigational Site
    Essen, 45122, Germany
  • Pfizer Investigational Site
    Frankfurt, 60590, Germany
  • Pfizer Investigational Site
    Freiburg, 79106, Germany
  • Pfizer Investigational Site
    Hamburg, 22081, Germany
  • Pfizer Investigational Site
    Bangalore, Karnataka 560 034, India
  • Pfizer Investigational Site
    Pune, Maharashtra 411 004, India
  • Pfizer Investigational Site
    Napoli, 80131, Italy
  • Pfizer Investigational Site
    Roma, 00128, Italy
  • Pfizer Investigational Site
    Roma, 00135, Italy
  • Pfizer Investigational Site
    Roma, 00144, Italy
  • Pfizer Investigational Site
    Rozzano (Mi), 20089, Italy
  • Pfizer Investigational Site
    Taormina, ME, 98039, Italy
  • Pfizer Investigational Site
    Hospitalet de Llobregat, Barcelona 08907, Spain
  • Pfizer Investigational Site
    Sabadell, Barcelona 08208, Spain
  • Pfizer Investigational Site
    Girona, 17007, Spain
  • Pfizer Investigational Site
    Madrid, 28040, Spain
  • Pfizer Investigational Site
    Madrid, 28041, Spain
  • Pfizer Investigational Site
    Malaga, 29010, Spain
  • Pfizer Investigational Site
    Valencia, 46009, Spain
  • Pfizer Investigational Site
    Valencia, 46010, Spain
  • Pfizer Investigational Site
    Southampton, Hampshire SO16 6YD, United Kingdom
  • Pfizer Investigational Site
    Rickmansworth, Middlesex HA5 2RN, United Kingdom
  • Pfizer Investigational Site
    Nottingham, Nottinghamshire NG5 1PB, United Kingdom
  • Pfizer Investigational Site
    Sheffield, Yorkshire S10 2SJ, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2004, a primary completion of Jan 2007 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 5 years 2 months after primary completion. A results delay was requested in Mar 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2004
First posted
Jan 14, 2004
Start
Feb 2004
Primary completionActual
Jan 2007
CompletionActual
Nov 2008
Results delay requested
Mar 20, 2009
Results first posted
Mar 16, 2012
Last update
Jun 26, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00076024
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 14, 2004
Start date
Feb 2004
Primary completion
Jan 2007
Completion
Nov 2008
Results posted
Mar 16, 2012
Last update
Jun 26, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion